Search for publications

Search results

4893 items matching your search terms.

Effects of fenofibrate on NMR-determined lipoprotein subclasses in type 2 diabetes patients from the FIELD study

Jenkins, A Best, J Otvos, J Forder, P Whiting, M Ehnholm, C Zannino, D Barter, P Sullivan, D Keech, A FIELD Study Investigators,


Chapter 54: Australia

Johnson, C Scott, K


K-ras mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer — results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care

Karapetis, C Khambata-Ford, S Jonker, D O’Callaghan, C Tu, D Vachan, B Simes, J Langer, C Moore, M Zalcberg, J
, 2008     DOI:10.1093/annonc/mdn649

K-ras mutations and benefit from cetuximab in advanced colorectal cancer

Karapetis, CS Khambata-Ford, S Jonker, DJ O'Callaghan, CJ Tu, D Tebbutt, NC Simes, RJ Chalchal, H Shapiro, JD Robitaille, S Price, TJ Shepherd, L Au, HJ Langer, C Moore, MJ Zalcberg, JR
NEW ENGLAND JOURNAL OF MEDICINE, 2008     DOI:doi:10.1056/NEJMoa0804385

Statins and diabetes: authors' reply [letter]

Kearney, PM Keech, A Simes, J Collins, R Baigent, C on behalf of the Cholesterol Treatment Trialists' (CTT) Collaboration,


Statins and diabetes - Authors' reply

Kearney, P. M. Keech, A. Simes, J. Collins, R. Baigent, C.
THE LANCET, 2008     DOI:10.1016/S0140-6736(08)60761-8

Fenofibrate and diabetic retinopathy - Authors' reply

Keech, A. Mitchell, P. Summanen, P. Davis, T. Simes, R.
THE LANCET, 2008     DOI:10.1016/S0140-6736(08)60335-9

Fenofibrate and diabetic retinopathy: authors' reply [letter]

Keech, AC; Mitchell, PM; Summanen, PA; Davis, TME; Simes, RJ


Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment

Lambert, G Ancellin, N Charlton, F Comas, D Pilot, J Keech, A Patel, S Sullivan, DR Cohn, JS Rye, KA Barter, PJ
CLINICAL CHEMISTRY, 2008     DOI:10.1373/clinchem.2007.099747

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment

Lambert, G. Ancellin, N. Charlton, F. Comas, D. Pilot, J. Keech, A. Patel, S. Sullivan, D. R. Cohn, J. S. Rye, K. A. Barter, P. J.
CLINICAL CHEMISTRY, 2008     DOI:10.1373/clinchem.2007.099747

Validity, responsiveness, and minimal important difference for the SF-6D health utility scale in a spinal cord injured population

Lee, BB King, MT Simpson, JM Haran, MJ Stockler, MR Marial, O Salkeld, G
VALUE IN HEALTH, 2008     DOI:10.1111/j.1524-4733.2007.00311.x